A Revolutionary Treatment for OCD in Horses

planning a number of human clinical trials within the UK and Ireland to evaluate the potential of this technology not only within the knee joint but also in other cartilaginous joints such as the ankle and shoulder. They are also investigating further use within the veterinary market and continue to use the material in veterinary case studies helping to prevent unnecessary deaths of animals that suffer with chronic disease conditions within their joints.
SurgaColl Technologies is exploring commercial opportunities of this scaffold for equine applications and they regularly receive requests from equine surgeons around the world including Kentucky United States and South Africa. The global interest underscores the significant veterinary market for new technologies that are proving to have such a positive effect on the welfare of horses.
SurgaColl has recently helped treat another horse with their other approved product an innovative orthobiologic bone graft substitute named HydroxyColl says Levingstone. It has similar composition to the bone healing layers of ChondroColl.
HydroxyColl combines bones two main ingredients collagen and hydroxyapatite in a bioactive scaffold to repair bone tissue defects. Collagen is a natural biopolymer a large molecule in a living organism. Hydroxyapatite is the natural ceramic mineral in bone tissue giving bones and teeth their rigidity. HydroxyColl directs bone regeneration and is completely replaced by newly formed healthy bone tissue.
Levingstone says that the procedure to treat a horse with HydroxyColl was done in the UK with the continued help of David Stack the veterinary surgeon who carried out the original treatment with Beyoncé. 
The products are currently applicable for veterinary use and the company has begun to explore potential sales and distribution opportunities she says. The unanimously positive endorsements from 100 percent of the veterinary surgeons that have helped develop andor worked with the final approved products has helped SurgaColl to attract potential partners and large veterinary practice groups that have a need for a costeffective solution with marketbeating performance in such large animals and defects.
She says that three human patients have been treated in a clinical study which investigated the human application of the scaffold. The study was led by RCSI Prof. Cathal Moran and Prof. John OByrne two consultant orthopaedic surgeons who have been pioneering the technology with very positive results.
SurgaColl has also started to engage a number of EU clinical sites and has received provisional ethical support for conducting a multisite randomized clinical trial to conclusively demonstrate the performance of